Meprobamate - DrugBank

ID Pharmacology Interactions References Trials Economics Properties Spectra Taxonomy

Targets (7)Enzymes (2)Transporters (1)

Targets (7)Enzymes (2)Transporters (1)Biointeractions (10)

Identification

Name

Meprobamate

Accession Number

DB00371 (APRD01095)

Type

Small Molecule

Groups

Approved, Illicit

Description

A carbamate with hypnotic, sedative, and some muscle relaxant properties, although in therapeutic doses reduction of anxiety rather than a direct effect may be responsible for muscle relaxation. Meprobamate has been reported to have anticonvulsant actions against petit mal seizures, but not against grand mal seizures (which may be exacerbated). It is used in the treatment of anxiety disorders, and also for the short-term management of insomnia but has largely been superseded by the benzodiazepines. (From Martindale, The Extra Pharmacopoeia, 30th ed, p603) Meprobamate is a controlled substance in the U.S.

Structure

MOL SDF 3D-SDF PDB SMILES InChI View 3D Structure

Synonyms

Equanil

Meprobamat

Meprobamato

Meprobamatum

Meprobamic acid

Miltown

External IDs

DEA No. 2820

Product Ingredients

Not Available

Approved Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Equanil Tablets 400mg	Tablet	400 mg	Oral	Wyeth Ayerst Canada Inc.	1994-12-31	2000-03-07	Canada
Meditran 400mg	Tablet	400 mg	Oral	Medic Laboratory LtÉe	1959-12-31	1996-09-09	Canada
Meprobamate Tab 400mg	Tablet	400 mg	Oral	Duchesnay Inc.	1978-12-31	2001-10-15	Canada
Meprobamate Tab 400mg	Tablet	400 mg	Oral	Pro Doc Limitee	1959-12-31	2001-10-15	Canada
Novo-mepro 200mg	Tablet	200 mg	Oral	Novopharm Limited	1967-12-31	2005-08-10	Canada
Novo-mepro 400mg	Tablet	400 mg	Oral	Novopharm Limited	1967-12-31	2005-08-10	Canada

Approved Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Apo Meprobamate Tab 400mg	Tablet	400 mg	Oral	Apotex Corporation	1975-12-31	2001-10-09	Canada
Meprobamate	Tablet	400 mg/1	Oral	Watson Pharmaceuticals	1973-05-03	Not applicable	US
Meprobamate	Tablet	200 mg/1	Oral	Dr Reddy's Laboratories	2008-01-03	Not applicable	US
Meprobamate	Tablet	200 mg/1	Oral	Heritage	2009-05-01	Not applicable	US
Meprobamate	Tablet	200 mg/1	Oral	Avera Mc Kennan Hospital	2015-11-03	Not applicable	US
Meprobamate	Tablet	400 mg/1	Oral	Alembic Pharmaceuticals Limited	2015-12-01	Not applicable	US
Meprobamate	Tablet	400 mg/1	Oral	Alembic Pharmaceuticals Limited	2013-07-23	Not applicable	US
Meprobamate	Tablet	200 mg/1	Oral	Taro Pharmaceutical Industries, Ltd.	2011-05-23	Not applicable	US
Meprobamate	Tablet	400 mg/1	Oral	Heritage	2009-05-01	Not applicable	US
Meprobamate	Tablet	200 mg/1	Oral	Watson Pharmaceuticals	1973-04-23	Not applicable	US
Meprobamate	Tablet	400 mg/1	Oral	Dr Reddy's Laboratories	2008-01-03	Not applicable	US
Meprobamate	Tablet	200 mg/1	Oral	Taro Pharmaceuticals U.S.A., Inc.	2011-05-23	Not applicable	US
Meprobamate	Tablet	400 mg/1	Oral	Taro Pharmaceutical Industries, Ltd.	2011-05-23	Not applicable	US
Meprobamate	Tablet	200 mg/1	Oral	Alembic Pharmaceuticals Limited	2015-12-01	Not applicable	US
Meprobamate	Tablet	200 mg/1	Oral	Alembic Pharmaceuticals Limited	2013-07-23	Not applicable	US
Meprobamate	Tablet	400 mg/1	Oral	Taro Pharmaceuticals U.S.A., Inc.	2011-05-23	Not applicable	US

Approved Over the Counter Products

Not Available

Unapproved/Other Products

Not Available

International Brands

Name	Company
Equanil	Wyeth
Meprospan	Not Available
Miltown	Wallace Laboratories

Brand mixtures

Name	Labeller	Ingredients
282 Mep Tab	Merck Frosst Canada & Cie, Merck Frosst Canada & Co.	Acetylsalicylic acid Caffeine Codeine Meprobamate
Equagesic Tablets	Wyeth Ayerst Canada Inc.	Acetylsalicylic acid Ethoheptazine Meprobamate

Categories

UNII

9I7LNY769Q

CAS number

57-53-4

Weight

Average: 218.2502
Monoisotopic: 218.126657074

Chemical Formula

C₉H₁₈N₂O₄

InChI Key

NPPQSCRMBWNHMW-UHFFFAOYSA-N

InChI

InChI=1S/C9H18N2O4/c1-3-4-9(2,5-14-7(10)12)6-15-8(11)13/h3-6H2,1-2H3,(H2,10,12)(H2,11,13)

IUPAC Name

2-[(carbamoyloxy)methyl]-2-methylpentyl carbamate

SMILES

CCCC(C)(COC(N)=O)COC(N)=O

Pharmacology

Indication

For the management of anxiety disorders or for the short-term relief of the symptoms of anxiety.

Structured Indications

Anxiety Disorder

Pharmacodynamics

Meprobamate is an anxiolytic drug. It was the best selling minor tranquilizer for a time but has largely been replaced by benzodiazepines. Meprobamate has most of the pharmacological effects and dangers of the barbiturates (though it was marketed as being safer). However, it is less sedating at effective doses. It is reported to have some anticonvulsant properties against absence seizures, but can exacerbate generalized tonic-clonic seizures. It has also been used as a hypnotic (sleeping pill). However, its is currently only licensed as an anxiolytic and it is a third or fourth-order choice.

Mechanism of action

Meprobamate's mechanism of action is not known. It has been shown in animal studies to have effects at multiple sites in the central nervous system, including the thalamus and limbic system. Meprobamate binds to GABA_A receptors which interrupt neuronal communication in the reticular formation and spinal cord, causing sedation and altered perception of pain.

Target	Kind	Pharmacological action	Actions	Organism	UniProt ID
Gamma-aminobutyric acid receptor subunit alpha-1	Protein	yes	agonist	Human	P14867	details
Gamma-aminobutyric acid receptor subunit alpha-2	Protein	yes	agonist	Human	P47869	details
Gamma-aminobutyric acid receptor subunit alpha-3	Protein	yes	agonist	Human	P34903	details
Gamma-aminobutyric acid receptor subunit alpha-4	Protein	yes	agonist	Human	P48169	details
Gamma-aminobutyric acid receptor subunit alpha-5	Protein	yes	agonist	Human	P31644	details
Gamma-aminobutyric acid receptor subunit alpha-6	Protein	yes	agonist	Human	Q16445	details
GABA-A receptor (anion channel)	Protein group	yes	positive allosteric modulator	Human	not applicable	details

Absorption

Well absorbed from the gastrointestinal tract.

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Hepatic.

Route of elimination

Not Available

Half life

Plasma half-life is about 10 hours.

Clearance

Not Available

Toxicity

Symptoms of overdose include coma, drowsiness, loss of muscle control, severely impaired breathing, shock, sluggishness, and unresponsiveness. Death has been reported with ingestion of as little as 12 g meprobamate and survival with as much as 40 g.

Affected organisms

Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
7-Nitroindazole	The risk or severity of adverse effects can be increased when Meprobamate is combined with 7-Nitroindazole.	Experimental
Abiraterone	The metabolism of Meprobamate can be decreased when combined with Abiraterone.	Approved
Acebutolol	The serum concentration of Acebutolol can be increased when it is combined with Meprobamate.	Approved
Acepromazine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Acepromazine.	Approved, Vet Approved
Aceprometazine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Aceprometazine.	Approved
Acetaminophen	The serum concentration of Acetaminophen can be increased when it is combined with Meprobamate.	Approved
Acetylsalicylic acid	The serum concentration of Acetylsalicylic acid can be increased when it is combined with Meprobamate.	Approved, Vet Approved
Adipiplon	The risk or severity of adverse effects can be increased when Meprobamate is combined with adipiplon.	Investigational
Afatinib	The serum concentration of Afatinib can be increased when it is combined with Meprobamate.	Approved
Agomelatine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Agomelatine.	Approved, Investigational
Aldosterone	The serum concentration of Aldosterone can be increased when it is combined with Meprobamate.	Experimental
Alfaxalone	The risk or severity of adverse effects can be increased when Meprobamate is combined with Alfaxalone.	Vet Approved
Alfentanil	The risk or severity of adverse effects can be increased when Meprobamate is combined with Alfentanil.	Approved, Illicit
Alitretinoin	The serum concentration of Alitretinoin can be increased when it is combined with Meprobamate.	Approved, Investigational
Allopregnanolone	The risk or severity of adverse effects can be increased when Meprobamate is combined with Sage 547.	Investigational
Alphacetylmethadol	The risk or severity of adverse effects can be increased when Meprobamate is combined with Alphacetylmethadol.	Experimental, Illicit
Alprazolam	The risk or severity of adverse effects can be increased when Meprobamate is combined with Alprazolam.	Approved, Illicit, Investigational
Ambrisentan	The serum concentration of Ambrisentan can be increased when it is combined with Meprobamate.	Approved, Investigational
Amisulpride	The risk or severity of adverse effects can be increased when Meprobamate is combined with Amisulpride.	Approved, Investigational
Amitriptyline	The serum concentration of Amitriptyline can be increased when it is combined with Meprobamate.	Approved
Amobarbital	The risk or severity of adverse effects can be increased when Meprobamate is combined with Amobarbital.	Approved, Illicit
Amoxapine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Amoxapine.	Approved
Amperozide	The risk or severity of adverse effects can be increased when Meprobamate is combined with Amperozide.	Experimental
Apixaban	The serum concentration of Apixaban can be increased when it is combined with Meprobamate.	Approved
Aripiprazole	The risk or severity of adverse effects can be increased when Meprobamate is combined with Aripiprazole.	Approved, Investigational
Armodafinil	The metabolism of Meprobamate can be decreased when combined with Armodafinil.	Approved, Investigational
Arsenic trioxide	The serum concentration of Arsenic trioxide can be increased when it is combined with Meprobamate.	Approved, Investigational
Articaine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Articaine.	Approved
Asenapine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Asenapine.	Approved
Atazanavir	The serum concentration of Atazanavir can be increased when it is combined with Meprobamate.	Approved, Investigational
Atenolol	The serum concentration of Atenolol can be increased when it is combined with Meprobamate.	Approved
Axitinib	The serum concentration of Axitinib can be increased when it is combined with Meprobamate.	Approved, Investigational
Azelastine	Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.	Approved
Azelastine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Azelastine.	Approved
Baclofen	The risk or severity of adverse effects can be increased when Meprobamate is combined with Baclofen.	Approved
Barbital	The risk or severity of adverse effects can be increased when Meprobamate is combined with Barbital.	Illicit
Benperidol	The risk or severity of adverse effects can be increased when Meprobamate is combined with Benperidol.	Investigational
Benzocaine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Benzocaine.	Approved
Benzyl alcohol	The risk or severity of adverse effects can be increased when Meprobamate is combined with Benzyl alcohol.	Approved
Betamethasone	The serum concentration of Betamethasone can be increased when it is combined with Meprobamate.	Approved, Vet Approved
Boceprevir	The serum concentration of Boceprevir can be increased when it is combined with Meprobamate.	Withdrawn
Bortezomib	The metabolism of Meprobamate can be decreased when combined with Bortezomib.	Approved, Investigational
Bosutinib	The serum concentration of Bosutinib can be increased when it is combined with Meprobamate.	Approved
Brentuximab vedotin	The serum concentration of Brentuximab vedotin can be increased when it is combined with Meprobamate.	Approved
Brexpiprazole	The risk or severity of adverse effects can be increased when Meprobamate is combined with Brexpiprazole.	Approved
Brimonidine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Brimonidine.	Approved
Brimonidine	Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.	Approved
Bromazepam	The risk or severity of adverse effects can be increased when Meprobamate is combined with Bromazepam.	Approved, Illicit
Bromocriptine	The serum concentration of Bromocriptine can be increased when it is combined with Meprobamate.	Approved, Investigational
Brompheniramine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Brompheniramine.	Approved
Brotizolam	The risk or severity of adverse effects can be increased when Meprobamate is combined with Brotizolam.	Approved, Withdrawn
Bupivacaine	The risk or severity of adverse effects can be increased when Bupivacaine is combined with Meprobamate.	Approved, Investigational
Buprenorphine	Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.	Approved, Illicit, Investigational, Vet Approved
Buspirone	The risk or severity of adverse effects can be increased when Meprobamate is combined with Buspirone.	Approved, Investigational
Butabarbital	The risk or severity of adverse effects can be increased when Butabarbital is combined with Meprobamate.	Approved, Illicit
Butalbital	The risk or severity of adverse effects can be increased when Meprobamate is combined with Butalbital.	Approved, Illicit
Butethal	The risk or severity of adverse effects can be increased when Meprobamate is combined with Butethal.	Approved, Illicit
Butorphanol	The risk or severity of adverse effects can be increased when Meprobamate is combined with Butorphanol.	Approved, Illicit, Vet Approved
Cabazitaxel	The serum concentration of Cabazitaxel can be increased when it is combined with Meprobamate.	Approved
Caffeine	The serum concentration of Caffeine can be increased when it is combined with Meprobamate.	Approved
Camptothecin	The serum concentration of Camptothecin can be increased when it is combined with Meprobamate.	Experimental
Canagliflozin	The serum concentration of Canagliflozin can be increased when it is combined with Meprobamate.	Approved
Carbamazepine	The metabolism of Meprobamate can be increased when combined with Carbamazepine.	Approved, Investigational
Carbinoxamine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Carbinoxamine.	Approved
Carfentanil	The risk or severity of adverse effects can be increased when Meprobamate is combined with Carfentanil.	Illicit, Vet Approved
Carfilzomib	The serum concentration of Carfilzomib can be increased when it is combined with Meprobamate.	Approved
Carisoprodol	The risk or severity of adverse effects can be increased when Meprobamate is combined with Carisoprodol.	Approved
Ceritinib	The serum concentration of Ceritinib can be increased when it is combined with Meprobamate.	Approved
Cerivastatin	The serum concentration of Cerivastatin can be increased when it is combined with Meprobamate.	Withdrawn
Cetirizine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Cetirizine.	Approved
Chloral hydrate	The risk or severity of adverse effects can be increased when Meprobamate is combined with Chloral hydrate.	Approved, Illicit, Vet Approved
Chloramphenicol	The metabolism of Meprobamate can be decreased when combined with Chloramphenicol.	Approved, Vet Approved
Chlordiazepoxide	The risk or severity of adverse effects can be increased when Meprobamate is combined with Chlordiazepoxide.	Approved, Illicit
Chlormezanone	The risk or severity of adverse effects can be increased when Meprobamate is combined with Chlormezanone.	Approved, Withdrawn
Chloroprocaine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Chloroprocaine.	Approved
Chlorphenamine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Chlorphenamine.	Approved
Chlorpromazine	The serum concentration of Chlorpromazine can be increased when it is combined with Meprobamate.	Approved, Vet Approved
Chlorprothixene	The risk or severity of adverse effects can be increased when Meprobamate is combined with Chlorprothixene.	Approved, Withdrawn
Chlorzoxazone	The risk or severity of adverse effects can be increased when Meprobamate is combined with Chlorzoxazone.	Approved
Cholecalciferol	The metabolism of Meprobamate can be decreased when combined with Cholecalciferol.	Approved, Nutraceutical
Cimetidine	The serum concentration of Cimetidine can be increased when it is combined with Meprobamate.	Approved
Cinchocaine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Cinchocaine.	Approved, Vet Approved
Ciprofloxacin	The serum concentration of Ciprofloxacin can be increased when it is combined with Meprobamate.	Approved, Investigational
Cisplatin	The serum concentration of Cisplatin can be increased when it is combined with Meprobamate.	Approved
Citalopram	The serum concentration of Citalopram can be increased when it is combined with Meprobamate.	Approved
Clarithromycin	The serum concentration of Clarithromycin can be increased when it is combined with Meprobamate.	Approved
Clemastine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Clemastine.	Approved
Clidinium	The risk or severity of adverse effects can be increased when Meprobamate is combined with Clidinium.	Approved
Clobazam	The serum concentration of Clobazam can be increased when it is combined with Meprobamate.	Approved, Illicit
Clomifene	The serum concentration of Clomifene can be increased when it is combined with Meprobamate.	Approved, Investigational
Clomipramine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Clomipramine.	Approved, Vet Approved
Clonazepam	The risk or severity of adverse effects can be increased when Meprobamate is combined with Clonazepam.	Approved, Illicit
Clonidine	The serum concentration of Clonidine can be increased when it is combined with Meprobamate.	Approved
Clopidogrel	The serum concentration of Clopidogrel can be increased when it is combined with Meprobamate.	Approved, Nutraceutical
Clorazepate	The risk or severity of adverse effects can be increased when Meprobamate is combined with Clorazepate.	Approved, Illicit
Clotrimazole	The metabolism of Meprobamate can be decreased when combined with Clotrimazole.	Approved, Vet Approved
Clozapine	The serum concentration of Clozapine can be increased when it is combined with Meprobamate.	Approved
Cobimetinib	The serum concentration of Cobimetinib can be increased when it is combined with Meprobamate.	Approved
Cocaine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Cocaine.	Approved, Illicit
Codeine	The risk or severity of adverse effects can be increased when Codeine is combined with Meprobamate.	Approved, Illicit
Colchicine	The serum concentration of Colchicine can be increased when it is combined with Meprobamate.	Approved
Conjugated estrogens	The serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Meprobamate.	Approved
Crizotinib	The serum concentration of Crizotinib can be increased when it is combined with Meprobamate.	Approved
Cyclizine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Cyclizine.	Approved
Cyclobenzaprine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Cyclobenzaprine.	Approved
Cyclosporine	The serum concentration of Cyclosporine can be increased when it is combined with Meprobamate.	Approved, Investigational, Vet Approved
Cyproheptadine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Cyproheptadine.	Approved
Cyproterone acetate	The serum concentration of Meprobamate can be decreased when it is combined with Cyproterone acetate.	Approved, Investigational
Dabigatran etexilate	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Meprobamate.	Approved
Dabrafenib	The serum concentration of Meprobamate can be decreased when it is combined with Dabrafenib.	Approved
Dactinomycin	The serum concentration of Dactinomycin can be increased when it is combined with Meprobamate.	Approved
Dantrolene	The risk or severity of adverse effects can be increased when Meprobamate is combined with Dantrolene.	Approved
Dapagliflozin	The serum concentration of Dapagliflozin can be increased when it is combined with Meprobamate.	Approved
Dapiprazole	The risk or severity of adverse effects can be increased when Dapiprazole is combined with Meprobamate.	Approved
Dapoxetine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Dapoxetine.	Investigational
Dasatinib	The serum concentration of Dasatinib can be increased when it is combined with Meprobamate.	Approved, Investigational
Daunorubicin	The serum concentration of Daunorubicin can be increased when it is combined with Meprobamate.	Approved
Debrisoquin	The serum concentration of Debrisoquin can be increased when it is combined with Meprobamate.	Approved
Delavirdine	The metabolism of Meprobamate can be decreased when combined with Delavirdine.	Approved
Deramciclane	The risk or severity of adverse effects can be increased when Meprobamate is combined with deramciclane.	Investigational
Desflurane	The risk or severity of adverse effects can be increased when Meprobamate is combined with Desflurane.	Approved
Desipramine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Desipramine.	Approved
Desloratadine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Desloratadine.	Approved, Investigational
Desvenlafaxine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Desvenlafaxine.	Approved
Dexamethasone	The serum concentration of Dexamethasone can be increased when it is combined with Meprobamate.	Approved, Investigational, Vet Approved
Dexbrompheniramine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Dexbrompheniramine.	Approved
Dexmedetomidine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Dexmedetomidine.	Approved, Vet Approved
Dextromoramide	The risk or severity of adverse effects can be increased when Meprobamate is combined with Dextromoramide.	Experimental, Illicit
Dextropropoxyphene	The risk or severity of adverse effects can be increased when Meprobamate is combined with Dextropropoxyphene.	Approved, Illicit, Withdrawn
Dezocine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Dezocine.	Approved
Diazepam	The serum concentration of Diazepam can be increased when it is combined with Meprobamate.	Approved, Illicit, Vet Approved
Diethylstilbestrol	The serum concentration of Diethylstilbestrol can be increased when it is combined with Meprobamate.	Approved
Difenoxin	The risk or severity of adverse effects can be increased when Meprobamate is combined with Difenoxin.	Approved, Illicit
Digitoxin	The serum concentration of Digitoxin can be increased when it is combined with Meprobamate.	Approved
Digoxin	The serum concentration of Digoxin can be increased when it is combined with Meprobamate.	Approved
Dihydrocodeine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Dihydrocodeine.	Approved, Illicit
Dihydroetorphine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Dihydroetorphine.	Experimental, Illicit
Dihydromorphine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Dihydromorphine.	Experimental, Illicit
Dihydrotestosterone	The serum concentration of Dihydrotestosterone can be increased when it is combined with Meprobamate.	Illicit
Diltiazem	The serum concentration of Diltiazem can be increased when it is combined with Meprobamate.	Approved
Dimenhydrinate	The risk or severity of adverse effects can be increased when Meprobamate is combined with Dimenhydrinate.	Approved
Diphenhydramine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Diphenhydramine.	Approved
Diphenoxylate	The risk or severity of adverse effects can be increased when Meprobamate is combined with Diphenoxylate.	Approved, Illicit
Dipyridamole	The serum concentration of Dipyridamole can be increased when it is combined with Meprobamate.	Approved
Disulfiram	The metabolism of Meprobamate can be decreased when combined with Disulfiram.	Approved
Docetaxel	The serum concentration of Docetaxel can be increased when it is combined with Meprobamate.	Approved, Investigational
Domperidone	The serum concentration of Domperidone can be increased when it is combined with Meprobamate.	Approved, Investigational, Vet Approved
Doxepin	The risk or severity of adverse effects can be increased when Meprobamate is combined with Doxepin.	Approved
Doxorubicin	The serum concentration of Doxorubicin can be increased when it is combined with Meprobamate.	Approved, Investigational
Doxylamine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.	Approved, Vet Approved
Dronabinol	Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.	Approved, Illicit
Droperidol	Droperidol may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.	Approved, Vet Approved
Drotebanol	The risk or severity of adverse effects can be increased when Meprobamate is combined with Drotebanol.	Experimental, Illicit
Duloxetine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Duloxetine.	Approved
Dyclonine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Dyclonine.	Approved
Ecgonine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Ecgonine.	Experimental, Illicit
Ecopipam	The risk or severity of adverse effects can be increased when Meprobamate is combined with Ecopipam.	Investigational
Edoxaban	The serum concentration of Edoxaban can be increased when it is combined with Meprobamate.	Approved
Efavirenz	The risk or severity of adverse effects can be increased when Meprobamate is combined with Efavirenz.	Approved, Investigational
Eletriptan	The serum concentration of Eletriptan can be increased when it is combined with Meprobamate.	Approved, Investigational
Eltanolone	The risk or severity of adverse effects can be increased when Meprobamate is combined with Pregnanolone.	Investigational
Enflurane	The risk or severity of adverse effects can be increased when Enflurane is combined with Meprobamate.	Approved, Vet Approved
Entacapone	The risk or severity of adverse effects can be increased when Meprobamate is combined with Entacapone.	Approved, Investigational
Epinastine	The serum concentration of Epinastine can be increased when it is combined with Meprobamate.	Approved, Investigational
Erlotinib	The serum concentration of Erlotinib can be increased when it is combined with Meprobamate.	Approved, Investigational
Erythromycin	The serum concentration of Erythromycin can be increased when it is combined with Meprobamate.	Approved, Vet Approved
Escitalopram	The risk or severity of adverse effects can be increased when Meprobamate is combined with Escitalopram.	Approved, Investigational
Eslicarbazepine acetate	The metabolism of Meprobamate can be decreased when combined with Eslicarbazepine acetate.	Approved
Esomeprazole	The metabolism of Meprobamate can be decreased when combined with Esomeprazole.	Approved, Investigational
Estazolam	The risk or severity of adverse effects can be increased when Meprobamate is combined with Estazolam.	Approved, Illicit
Estradiol	The serum concentration of Estradiol can be increased when it is combined with Meprobamate.	Approved, Investigational, Vet Approved
Estriol	The serum concentration of Estriol can be increased when it is combined with Meprobamate.	Approved, Vet Approved
Estrone	The serum concentration of Estrone can be increased when it is combined with Meprobamate.	Approved
Eszopiclone	The risk or severity of adverse effects can be increased when Meprobamate is combined with Eszopiclone.	Approved
Ethanol	Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.	Approved
Ethchlorvynol	The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Meprobamate.	Approved, Illicit, Withdrawn
Ethinyl Estradiol	The serum concentration of Ethinyl Estradiol can be increased when it is combined with Meprobamate.	Approved
Ethosuximide	The risk or severity of adverse effects can be increased when Meprobamate is combined with Ethosuximide.	Approved
Ethotoin	The risk or severity of adverse effects can be increased when Meprobamate is combined with Ethotoin.	Approved
Ethyl carbamate	The risk or severity of adverse effects can be increased when Meprobamate is combined with Ethyl carbamate.	Withdrawn
Ethyl loflazepate	The risk or severity of adverse effects can be increased when Meprobamate is combined with Ethyl loflazepate.	Approved, Illicit
Ethylmorphine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Ethylmorphine.	Approved, Illicit
Etidocaine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Etidocaine.	Approved
Etifoxine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Etifoxine.	Withdrawn
Etizolam	The risk or severity of adverse effects can be increased when Meprobamate is combined with Etizolam.	Approved
Etomidate	The risk or severity of adverse effects can be increased when Etomidate is combined with Meprobamate.	Approved
Etoperidone	The risk or severity of adverse effects can be increased when Meprobamate is combined with Etoperidone.	Approved
Etoposide	The serum concentration of Etoposide can be increased when it is combined with Meprobamate.	Approved
Etorphine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Etorphine.	Illicit, Vet Approved
Etravirine	The metabolism of Meprobamate can be decreased when combined with Etravirine.	Approved
Everolimus	The serum concentration of Everolimus can be increased when it is combined with Meprobamate.	Approved
Ezetimibe	The serum concentration of Ezetimibe can be increased when it is combined with Meprobamate.	Approved
Ezogabine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Ezogabine.	Approved
Felbamate	The risk or severity of adverse effects can be increased when Meprobamate is combined with Felbamate.	Approved
Fencamfamine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Fencamfamine.	Approved, Illicit, Withdrawn
Fentanyl	The risk or severity of adverse effects can be increased when Meprobamate is combined with Fentanyl.	Approved, Illicit, Investigational, Vet Approved
Fesoterodine	The serum concentration of Fesoterodine can be increased when it is combined with Meprobamate.	Approved
Fexofenadine	The serum concentration of Fexofenadine can be increased when it is combined with Meprobamate.	Approved
Fidaxomicin	The serum concentration of Fidaxomicin can be increased when it is combined with Meprobamate.	Approved
Flibanserin	The risk or severity of adverse effects can be increased when Meprobamate is combined with Flibanserin.	Approved
Fluconazole	The metabolism of Meprobamate can be decreased when combined with Fluconazole.	Approved
Fludiazepam	The risk or severity of adverse effects can be increased when Meprobamate is combined with Fludiazepam.	Approved, Illicit
Flunarizine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Flunarizine.	Approved
Flunitrazepam	The risk or severity of adverse effects can be increased when Meprobamate is combined with Flunitrazepam.	Approved, Illicit
Fluoxetine	The metabolism of Meprobamate can be decreased when combined with Fluoxetine.	Approved, Vet Approved
Flupentixol	The risk or severity of adverse effects can be increased when Meprobamate is combined with Flupentixol.	Approved, Withdrawn
Fluphenazine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Fluphenazine.	Approved
Flurazepam	The risk or severity of adverse effects can be increased when Meprobamate is combined with Flurazepam.	Approved, Illicit
Fluspirilene	The risk or severity of adverse effects can be increased when Meprobamate is combined with Fluspirilene.	Approved
Fluticasone furoate	The serum concentration of Fluticasone furoate can be increased when it is combined with Meprobamate.	Approved
Fluticasone propionate	The risk or severity of adverse effects can be increased when Meprobamate is combined with Fluticasone Propionate.	Approved
Fluvoxamine	The metabolism of Meprobamate can be decreased when combined with Fluvoxamine.	Approved, Investigational
Fosphenytoin	The metabolism of Meprobamate can be increased when combined with Fosphenytoin.	Approved
Fospropofol	The risk or severity of adverse effects can be increased when Meprobamate is combined with Fospropofol.	Approved, Illicit
Gabapentin	The risk or severity of adverse effects can be increased when Meprobamate is combined with Gabapentin.	Approved, Investigational
Gabapentin Enacarbil	The risk or severity of adverse effects can be increased when Meprobamate is combined with gabapentin enacarbil.	Approved
Gamma Hydroxybutyric Acid	The risk or severity of adverse effects can be increased when Meprobamate is combined with Gamma Hydroxybutyric Acid.	Approved, Illicit
Gefitinib	The serum concentration of Gefitinib can be increased when it is combined with Meprobamate.	Approved, Investigational
Gemcitabine	The serum concentration of Gemcitabine can be increased when it is combined with Meprobamate.	Approved
Gemfibrozil	The metabolism of Meprobamate can be decreased when combined with Gemfibrozil.	Approved
Gepirone	The risk or severity of adverse effects can be increased when Meprobamate is combined with Gepirone.	Investigational
Glutethimide	The risk or severity of adverse effects can be increased when Meprobamate is combined with Glutethimide.	Approved, Illicit
Grazoprevir	The serum concentration of Grazoprevir can be increased when it is combined with Meprobamate.	Approved
Grepafloxacin	The serum concentration of Grepafloxacin can be increased when it is combined with Meprobamate.	Withdrawn
Guanfacine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Guanfacine.	Approved, Investigational
Halazepam	The risk or severity of adverse effects can be increased when Meprobamate is combined with Halazepam.	Approved, Illicit, Withdrawn
Haloperidol	The serum concentration of Haloperidol can be increased when it is combined with Meprobamate.	Approved
Halothane	The risk or severity of adverse effects can be increased when Meprobamate is combined with Halothane.	Approved, Vet Approved
Heroin	The risk or severity of adverse effects can be increased when Meprobamate is combined with Heroin.	Approved, Illicit
Hexobarbital	The risk or severity of adverse effects can be increased when Meprobamate is combined with Hexobarbital.	Approved
Hydrocodone	Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.	Approved, Illicit
Hydrocortisone	The serum concentration of Hydrocortisone can be increased when it is combined with Meprobamate.	Approved, Vet Approved
Hydromorphone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Meprobamate.	Approved, Illicit
Hydroxyzine	Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.	Approved
Ibuprofen	The serum concentration of Ibuprofen can be increased when it is combined with Meprobamate.	Approved
Idelalisib	The serum concentration of Idelalisib can be increased when it is combined with Meprobamate.	Approved
Iloperidone	The risk or severity of adverse effects can be increased when Meprobamate is combined with Iloperidone.	Approved
Imatinib	The serum concentration of Imatinib can be increased when it is combined with Meprobamate.	Approved
Imipramine	The serum concentration of Imipramine can be increased when it is combined with Meprobamate.	Approved
Indacaterol	The serum concentration of Indacaterol can be increased when it is combined with Meprobamate.	Approved
Indalpine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Indalpine.	Investigational, Withdrawn
Indinavir	The serum concentration of Indinavir can be increased when it is combined with Meprobamate.	Approved
Indomethacin	The serum concentration of Indomethacin can be increased when it is combined with Meprobamate.	Approved, Investigational
Irinotecan	The serum concentration of Irinotecan can be increased when it is combined with Meprobamate.	Approved, Investigational
Isoflurane	The risk or severity of adverse effects can be increased when Meprobamate is combined with Isoflurane.	Approved, Vet Approved
Isoniazid	The metabolism of Meprobamate can be decreased when combined with Isoniazid.	Approved
Ivermectin	The serum concentration of Ivermectin can be increased when it is combined with Meprobamate.	Approved, Vet Approved
Ketamine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Ketamine.	Approved, Vet Approved
Ketazolam	The serum concentration of Ketazolam can be increased when it is combined with Meprobamate.	Approved
Ketobemidone	The risk or severity of adverse effects can be increased when Meprobamate is combined with Ketobemidone.	Approved
Ketoconazole	The serum concentration of Ketoconazole can be increased when it is combined with Meprobamate.	Approved, Investigational
Lamivudine	The serum concentration of Lamivudine can be increased when it is combined with Meprobamate.	Approved, Investigational
Lamotrigine	The serum concentration of Lamotrigine can be increased when it is combined with Meprobamate.	Approved, Investigational
Lansoprazole	The serum concentration of Lansoprazole can be increased when it is combined with Meprobamate.	Approved, Investigational
Ledipasvir	The serum concentration of Ledipasvir can be increased when it is combined with Meprobamate.	Approved
Lenalidomide	The serum concentration of Lenalidomide can be increased when it is combined with Meprobamate.	Approved
Lenvatinib	The serum concentration of Lenvatinib can be increased when it is combined with Meprobamate.	Approved
Levetiracetam	The serum concentration of Levetiracetam can be increased when it is combined with Meprobamate.	Approved, Investigational
Levobupivacaine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Levobupivacaine.	Approved
Levocabastine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Levocabastine.	Approved
Levocetirizine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Levocetirizine.	Approved
Levodopa	The risk or severity of adverse effects can be increased when Meprobamate is combined with Levodopa.	Approved
Levofloxacin	The serum concentration of Levofloxacin can be increased when it is combined with Meprobamate.	Approved, Investigational
Levomethadyl Acetate	The risk or severity of adverse effects can be increased when Meprobamate is combined with Levomethadyl Acetate.	Approved
Levomilnacipran	The serum concentration of Levomilnacipran can be increased when it is combined with Meprobamate.	Approved
Levorphanol	The risk or severity of adverse effects can be increased when Meprobamate is combined with Levorphanol.	Approved
Lidocaine	The risk or severity of adverse effects can be increased when Lidocaine is combined with Meprobamate.	Approved, Vet Approved
Linagliptin	The serum concentration of Linagliptin can be increased when it is combined with Meprobamate.	Approved
Lithium	The risk or severity of adverse effects can be increased when Meprobamate is combined with Lithium.	Approved
Lofentanil	The risk or severity of adverse effects can be increased when Meprobamate is combined with Lofentanil.	Illicit
Loperamide	The serum concentration of Loperamide can be increased when it is combined with Meprobamate.	Approved
Lopinavir	The metabolism of Meprobamate can be increased when combined with Lopinavir.	Approved
Loratadine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Loratadine.	Approved
Lorazepam	The risk or severity of adverse effects can be increased when Lorazepam is combined with Meprobamate.	Approved
Losartan	The serum concentration of Losartan can be increased when it is combined with Meprobamate.	Approved
Loxapine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Loxapine.	Approved
Luliconazole	The serum concentration of Meprobamate can be increased when it is combined with Luliconazole.	Approved
Lumacaftor	The serum concentration of Meprobamate can be decreased when it is combined with Lumacaftor.	Approved
Lurasidone	The risk or severity of adverse effects can be increased when Meprobamate is combined with Lurasidone.	Approved
Magnesium Sulfate	Magnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.	Approved, Vet Approved
Mannitol	The serum concentration of Mannitol can be increased when it is combined with Meprobamate.	Approved, Investigational
Maprotiline	The risk or severity of adverse effects can be increased when Meprobamate is combined with Maprotiline.	Approved
Meclizine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Meclizine.	Approved
Mefloquine	The therapeutic efficacy of Meprobamate can be decreased when used in combination with Mefloquine.	Approved
Melatonin	The risk or severity of adverse effects can be increased when Meprobamate is combined with Melatonin.	Approved, Nutraceutical, Vet Approved
Melperone	The risk or severity of adverse effects can be increased when Meprobamate is combined with Melperone.	Approved
Mepivacaine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Mepivacaine.	Approved, Vet Approved
Mesoridazine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Mesoridazine.	Approved
Metaxalone	The risk or severity of adverse effects can be increased when Meprobamate is combined with Metaxalone.	Approved
Methadone	The risk or severity of adverse effects can be increased when Methadone is combined with Meprobamate.	Approved
Methadyl Acetate	The risk or severity of adverse effects can be increased when Meprobamate is combined with Methadyl Acetate.	Approved, Illicit
Methapyrilene	The risk or severity of adverse effects can be increased when Meprobamate is combined with Methapyrilene.	Withdrawn
Methaqualone	The risk or severity of adverse effects can be increased when Meprobamate is combined with Methaqualone.	Illicit, Withdrawn
Methocarbamol	The risk or severity of adverse effects can be increased when Meprobamate is combined with Methocarbamol.	Approved, Vet Approved
Methohexital	The risk or severity of adverse effects can be increased when Meprobamate is combined with Methohexital.	Approved
Methotrexate	The serum concentration of Methotrexate can be increased when it is combined with Meprobamate.	Approved
Methotrimeprazine	Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.	Approved
Methoxyflurane	The risk or severity of adverse effects can be increased when Meprobamate is combined with Methoxyflurane.	Approved, Vet Approved
Methsuximide	The risk or severity of adverse effects can be increased when Meprobamate is combined with Methsuximide.	Approved
Methylecgonine	The risk or severity of adverse effects can be increased when Meprobamate is combined with ECGONINE METHYL ESTER.	Experimental
Methylphenobarbital	The risk or severity of adverse effects can be increased when Meprobamate is combined with Methylphenobarbital.	Approved
Methylprednisolone	The serum concentration of Methylprednisolone can be increased when it is combined with Meprobamate.	Approved, Vet Approved
Metoprolol	The serum concentration of Metoprolol can be increased when it is combined with Meprobamate.	Approved, Investigational
Metyrosine	Meprobamate may increase the sedative activities of Metyrosine.	Approved
Mianserin	The therapeutic efficacy of Meprobamate can be decreased when used in combination with Mianserin.	Approved
Midazolam	The serum concentration of Midazolam can be increased when it is combined with Meprobamate.	Approved, Illicit
Milnacipran	The risk or severity of adverse effects can be increased when Meprobamate is combined with Milnacipran.	Approved
Minocycline	Minocycline may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.	Approved, Investigational
Mirabegron	The serum concentration of Mirabegron can be increased when it is combined with Meprobamate.	Approved
Mirtazapine	Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.	Approved
Mitoxantrone	The serum concentration of Mitoxantrone can be increased when it is combined with Meprobamate.	Approved, Investigational
Moclobemide	The metabolism of Meprobamate can be decreased when combined with Moclobemide.	Approved
Modafinil	The metabolism of Meprobamate can be decreased when combined with Modafinil.	Approved, Investigational
Molindone	The risk or severity of adverse effects can be increased when Meprobamate is combined with Molindone.	Approved
Morphine	The serum concentration of Morphine can be increased when it is combined with Meprobamate.	Approved, Investigational
Mycophenolate mofetil	The serum concentration of Mycophenolate mofetil can be increased when it is combined with Meprobamate.	Approved, Investigational
Nabilone	Nabilone may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.	Approved, Investigational
Nadolol	The serum concentration of Nadolol can be increased when it is combined with Meprobamate.	Approved
Nalbuphine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Nalbuphine.	Approved
Naloxegol	The serum concentration of Naloxegol can be increased when it is combined with Meprobamate.	Approved
Naloxone	The serum concentration of Naloxone can be increased when it is combined with Meprobamate.	Approved, Vet Approved
Nefazodone	The risk or severity of adverse effects can be increased when Meprobamate is combined with Nefazodone.	Approved, Withdrawn
Nelfinavir	The serum concentration of Nelfinavir can be increased when it is combined with Meprobamate.	Approved
Nicardipine	The serum concentration of Nicardipine can be increased when it is combined with Meprobamate.	Approved
Nicotine	The metabolism of Meprobamate can be decreased when combined with Nicotine.	Approved
Nifedipine	The serum concentration of Nifedipine can be increased when it is combined with Meprobamate.	Approved
Nilotinib	The serum concentration of Nilotinib can be increased when it is combined with Meprobamate.	Approved, Investigational
Nintedanib	The serum concentration of Nintedanib can be increased when it is combined with Meprobamate.	Approved
Nitrazepam	The risk or severity of adverse effects can be increased when Meprobamate is combined with Nitrazepam.	Approved
Nitrous oxide	The risk or severity of adverse effects can be increased when Meprobamate is combined with Nitrous oxide.	Approved, Vet Approved
Nizatidine	The serum concentration of Nizatidine can be increased when it is combined with Meprobamate.	Approved
Norflurane	The risk or severity of adverse effects can be increased when Meprobamate is combined with 1,1,1,2 Tetrafluoroethane.	Investigational
Normethadone	The risk or severity of adverse effects can be increased when Meprobamate is combined with Normethadone.	Approved, Illicit
Nortriptyline	The risk or severity of adverse effects can be increased when Meprobamate is combined with Nortriptyline.	Approved
Olanzapine	The serum concentration of Olanzapine can be increased when it is combined with Meprobamate.	Approved, Investigational
Olopatadine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Olopatadine.	Approved
Ombitasvir	The serum concentration of Ombitasvir can be increased when it is combined with Meprobamate.	Approved
Omeprazole	The metabolism of Meprobamate can be decreased when combined with Omeprazole.	Approved, Investigational, Vet Approved
Ondansetron	The risk or severity of adverse effects can be increased when Meprobamate is combined with Ondansetron.	Approved
Opium	The risk or severity of adverse effects can be increased when Meprobamate is combined with Opium.	Approved, Illicit
Orlistat	The serum concentration of Meprobamate can be decreased when it is combined with Orlistat.	Approved, Investigational
Orphenadrine	Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.	Approved
Osanetant	The risk or severity of adverse effects can be increased when Meprobamate is combined with Osanetant.	Investigational
Osimertinib	The serum concentration of Osimertinib can be increased when it is combined with Meprobamate.	Approved
Oxazepam	The risk or severity of adverse effects can be increased when Meprobamate is combined with Oxazepam.	Approved
Oxethazaine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Oxetacaine.	Investigational
Oxprenolol	The risk or severity of adverse effects can be increased when Meprobamate is combined with Oxprenolol.	Approved
Oxybuprocaine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Oxybuprocaine.	Approved
Oxycodone	The risk or severity of adverse effects can be increased when Meprobamate is combined with Oxycodone.	Approved, Illicit, Investigational
Oxymorphone	The risk or severity of adverse effects can be increased when Meprobamate is combined with Oxymorphone.	Approved, Investigational, Vet Approved
Paclitaxel	The serum concentration of Paclitaxel can be increased when it is combined with Meprobamate.	Approved, Vet Approved
Paliperidone	The risk or severity of adverse effects can be increased when Meprobamate is combined with Paliperidone.	Approved
Panobinostat	The serum concentration of Panobinostat can be increased when it is combined with Meprobamate.	Approved, Investigational
Pantoprazole	The metabolism of Meprobamate can be decreased when combined with Pantoprazole.	Approved
Paraldehyde	Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.	Approved
Paroxetine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Paroxetine.	Approved, Investigational
Pazopanib	The serum concentration of Pazopanib can be increased when it is combined with Meprobamate.	Approved
Pentazocine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Pentazocine.	Approved, Vet Approved
Pentobarbital	The risk or severity of adverse effects can be increased when Pentobarbital is combined with Meprobamate.	Approved, Vet Approved
Perampanel	Perampanel may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.	Approved
Perazine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Perazine.	Investigational
Perospirone	The risk or severity of adverse effects can be increased when Meprobamate is combined with Perospirone.	Approved
Perphenazine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Perphenazine.	Approved
Pethidine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Pethidine.	Approved
Phenobarbital	The serum concentration of Phenobarbital can be increased when it is combined with Meprobamate.	Approved
Phenytoin	The metabolism of Meprobamate can be increased when combined with Phenytoin.	Approved, Vet Approved
Pimozide	The risk or severity of adverse effects can be increased when Meprobamate is combined with Pimozide.	Approved
Pipamperone	The risk or severity of adverse effects can be increased when Meprobamate is combined with Pipamperone.	Approved
Pipotiazine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Pipotiazine.	Approved
Piritramide	The risk or severity of adverse effects can be increased when Meprobamate is combined with Piritramide.	Investigational
Pitavastatin	The serum concentration of Pitavastatin can be increased when it is combined with Meprobamate.	Approved
Pomalidomide	The serum concentration of Pomalidomide can be increased when it is combined with Meprobamate.	Approved
Ponatinib	The serum concentration of Ponatinib can be increased when it is combined with Meprobamate.	Approved
Pramipexole	Meprobamate may increase the sedative activities of Pramipexole.	Approved, Investigational
Pramocaine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Pramocaine.	Approved
Pravastatin	The serum concentration of Pravastatin can be increased when it is combined with Meprobamate.	Approved
Prazepam	The risk or severity of adverse effects can be increased when Meprobamate is combined with Prazepam.	Approved, Illicit
Prazosin	The serum concentration of Prazosin can be increased when it is combined with Meprobamate.	Approved
Prednisolone	The serum concentration of Prednisolone can be increased when it is combined with Meprobamate.	Approved, Vet Approved
Prednisone	The serum concentration of Prednisone can be increased when it is combined with Meprobamate.	Approved, Vet Approved
Pregabalin	The risk or severity of adverse effects can be increased when Pregabalin is combined with Meprobamate.	Approved, Illicit, Investigational
Prilocaine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Prilocaine.	Approved
Primidone	The risk or severity of adverse effects can be increased when Meprobamate is combined with Primidone.	Approved, Vet Approved
Procaine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Procaine.	Approved, Investigational, Vet Approved
Prochlorperazine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Prochlorperazine.	Approved, Vet Approved
Progesterone	The serum concentration of Progesterone can be increased when it is combined with Meprobamate.	Approved, Vet Approved
Promazine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Promazine.	Approved, Vet Approved
Promethazine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Promethazine.	Approved
Proparacaine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Proparacaine.	Approved, Vet Approved
Propofol	The risk or severity of adverse effects can be increased when Meprobamate is combined with Propofol.	Approved, Investigational, Vet Approved
Propoxycaine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Propoxycaine.	Approved
Propranolol	The serum concentration of Propranolol can be increased when it is combined with Meprobamate.	Approved, Investigational
Protriptyline	The risk or severity of adverse effects can be increased when Meprobamate is combined with Protriptyline.	Approved
Prucalopride	The serum concentration of Prucalopride can be increased when it is combined with Meprobamate.	Approved
Quazepam	The risk or severity of adverse effects can be increased when Meprobamate is combined with Quazepam.	Approved, Illicit
Quetiapine	The serum concentration of Quetiapine can be increased when it is combined with Meprobamate.	Approved
Quinidine	The serum concentration of Quinidine can be increased when it is combined with Meprobamate.	Approved
Quinine	The serum concentration of Quinine can be increased when it is combined with Meprobamate.	Approved
Raclopride	The risk or severity of adverse effects can be increased when Meprobamate is combined with Raclopride.	Investigational
Ramelteon	The risk or severity of adverse effects can be increased when Meprobamate is combined with Ramelteon.	Approved, Investigational
Ranitidine	The serum concentration of Ranitidine can be increased when it is combined with Meprobamate.	Approved
Ranolazine	The serum concentration of Ranolazine can be increased when it is combined with Meprobamate.	Approved, Investigational
Remifentanil	The risk or severity of adverse effects can be increased when Meprobamate is combined with Remifentanil.	Approved
Remoxipride	The risk or severity of adverse effects can be increased when Meprobamate is combined with Remoxipride.	Approved, Withdrawn
Reserpine	The serum concentration of Reserpine can be increased when it is combined with Meprobamate.	Approved
Rifampicin	The metabolism of Meprobamate can be increased when combined with Rifampicin.	Approved
Rifaximin	The serum concentration of Rifaximin can be increased when it is combined with Meprobamate.	Approved, Investigational
Risperidone	The serum concentration of Risperidone can be increased when it is combined with Meprobamate.	Approved, Investigational
Ritanserin	The risk or severity of adverse effects can be increased when Meprobamate is combined with Ritanserin.	Investigational
Ritonavir	The serum concentration of Ritonavir can be increased when it is combined with Meprobamate.	Approved, Investigational
Rivaroxaban	The serum concentration of Rivaroxaban can be increased when it is combined with Meprobamate.	Approved
Romidepsin	The serum concentration of Romidepsin can be increased when it is combined with Meprobamate.	Approved, Investigational
Ropinirole	Meprobamate may increase the sedative activities of Ropinirole.	Approved, Investigational
Ropivacaine	The risk or severity of adverse effects can be increased when Ropivacaine is combined with Meprobamate.	Approved
Rotigotine	Meprobamate may increase the sedative activities of Rotigotine.	Approved
Rufinamide	The risk or severity of adverse effects can be increased when Rufinamide is combined with Meprobamate.	Approved
Salicylic acid	The serum concentration of Salicylic acid can be increased when it is combined with Meprobamate.	Approved, Vet Approved
Saquinavir	The serum concentration of Saquinavir can be increased when it is combined with Meprobamate.	Approved, Investigational
Scopolamine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Scopolamine.	Approved
Secobarbital	The risk or severity of adverse effects can be increased when Meprobamate is combined with Secobarbital.	Approved, Vet Approved
Selexipag	The serum concentration of Selexipag can be increased when it is combined with Meprobamate.	Approved
Sepranolone	The risk or severity of adverse effects can be increased when Meprobamate is combined with Uc1010.	Investigational
Sertindole	The risk or severity of adverse effects can be increased when Meprobamate is combined with Sertindole.	Approved, Withdrawn
Sertraline	The metabolism of Meprobamate can be decreased when combined with Sertraline.	Approved
Sevoflurane	The risk or severity of adverse effects can be increased when Meprobamate is combined with Sevoflurane.	Approved, Vet Approved
Silodosin	The serum concentration of Silodosin can be increased when it is combined with Meprobamate.	Approved
Simeprevir	The serum concentration of Simeprevir can be increased when it is combined with Meprobamate.	Approved
Sitagliptin	The serum concentration of Sitagliptin can be increased when it is combined with Meprobamate.	Approved, Investigational
Sodium oxybate	Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.	Approved
Sofosbuvir	The serum concentration of Sofosbuvir can be increased when it is combined with Meprobamate.	Approved
Sorafenib	The serum concentration of Sorafenib can be increased when it is combined with Meprobamate.	Approved, Investigational
Sparfloxacin	The serum concentration of Sparfloxacin can be increased when it is combined with Meprobamate.	Approved
Sphingosine	The serum concentration of Sphingosine can be increased when it is combined with Meprobamate.	Experimental
Stiripentol	The metabolism of Meprobamate can be decreased when combined with Stiripentol.	Approved
Sufentanil	The risk or severity of adverse effects can be increased when Meprobamate is combined with Sufentanil.	Approved, Investigational
Sulpiride	The risk or severity of adverse effects can be increased when Meprobamate is combined with Sulpiride.	Approved
Suvorexant	Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.	Approved
Tacrolimus	The serum concentration of Tacrolimus can be increased when it is combined with Meprobamate.	Approved, Investigational
Tamoxifen	The serum concentration of Tamoxifen can be increased when it is combined with Meprobamate.	Approved
Tandospirone	The risk or severity of adverse effects can be increased when Meprobamate is combined with Tandospirone.	Investigational
Tapentadol	Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.	Approved
Tasimelteon	The risk or severity of adverse effects can be increased when Meprobamate is combined with Tasimelteon.	Approved
Taurocholic Acid	The serum concentration of Taurocholic Acid can be increased when it is combined with Meprobamate.	Experimental
Technetium Tc-99m sestamibi	The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Meprobamate.	Approved
Telaprevir	The serum concentration of Telaprevir can be increased when it is combined with Meprobamate.	Withdrawn
Temazepam	The risk or severity of adverse effects can be increased when Temazepam is combined with Meprobamate.	Approved
Temsirolimus	The serum concentration of Temsirolimus can be increased when it is combined with Meprobamate.	Approved
Tetrabenazine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Tetrabenazine.	Approved
Tetracaine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Tetracaine.	Approved, Vet Approved
Tetrodotoxin	The risk or severity of adverse effects can be increased when Meprobamate is combined with Tetrodotoxin.	Investigational
Thalidomide	Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.	Approved, Investigational, Withdrawn
Thiamylal	The risk or severity of adverse effects can be increased when Meprobamate is combined with Thiamylal.	Approved, Vet Approved
Thiopental	The risk or severity of adverse effects can be increased when Meprobamate is combined with Thiopental.	Approved, Vet Approved
Thioridazine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Thioridazine.	Withdrawn
Thiothixene	The risk or severity of adverse effects can be increased when Meprobamate is combined with Thiothixene.	Approved
Tiagabine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Tiagabine.	Approved
Tiapride	The risk or severity of adverse effects can be increased when Meprobamate is combined with Tiapride.	Approved, Investigational
Ticagrelor	The serum concentration of Ticagrelor can be increased when it is combined with Meprobamate.	Approved
Ticlopidine	The metabolism of Meprobamate can be decreased when combined with Ticlopidine.	Approved
Timolol	The serum concentration of Timolol can be increased when it is combined with Meprobamate.	Approved
Tizanidine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Tizanidine.	Approved
Tolcapone	The risk or severity of adverse effects can be increased when Meprobamate is combined with Tolcapone.	Approved, Withdrawn
Tolvaptan	The serum concentration of Tolvaptan can be increased when it is combined with Meprobamate.	Approved
Topiramate	The risk or severity of adverse effects can be increased when Meprobamate is combined with Topiramate.	Approved
Topotecan	The serum concentration of Topotecan can be increased when it is combined with Meprobamate.	Approved, Investigational
Toremifene	The serum concentration of Toremifene can be increased when it is combined with Meprobamate.	Approved, Investigational
Tramadol	The risk or severity of adverse effects can be increased when Tramadol is combined with Meprobamate.	Approved, Investigational
Trans-2-Phenylcyclopropylamine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Trans-2-Phenylcyclopropylamine.	Experimental
Tranylcypromine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Tranylcypromine.	Approved
Trastuzumab emtansine	The serum concentration of Trastuzumab emtansine can be increased when it is combined with Meprobamate.	Approved
Trazodone	The risk or severity of adverse effects can be increased when Meprobamate is combined with Trazodone.	Approved, Investigational
Triazolam	The risk or severity of adverse effects can be increased when Meprobamate is combined with Triazolam.	Approved
Trifluoperazine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Trifluoperazine.	Approved
Triflupromazine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Triflupromazine.	Approved, Vet Approved
Trimipramine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Trimipramine.	Approved
Triprolidine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Triprolidine.	Approved
Ulipristal	The serum concentration of Ulipristal can be increased when it is combined with Meprobamate.	Approved
Umeclidinium	The serum concentration of Umeclidinium can be increased when it is combined with Meprobamate.	Approved
Valproic Acid	The risk or severity of adverse effects can be increased when Valproic Acid is combined with Meprobamate.	Approved, Investigational
Vecuronium	The serum concentration of Vecuronium can be increased when it is combined with Meprobamate.	Approved
Venetoclax	The serum concentration of Venetoclax can be increased when it is combined with Meprobamate.	Approved
Venlafaxine	The serum concentration of Venlafaxine can be increased when it is combined with Meprobamate.	Approved
Verapamil	The serum concentration of Verapamil can be increased when it is combined with Meprobamate.	Approved
Vigabatrin	The risk or severity of adverse effects can be increased when Meprobamate is combined with Vigabatrin.	Approved
Vinblastine	The serum concentration of Vinblastine can be increased when it is combined with Meprobamate.	Approved
Vincristine	The serum concentration of Vincristine can be increased when it is combined with Meprobamate.	Approved, Investigational
Vismodegib	The serum concentration of Vismodegib can be increased when it is combined with Meprobamate.	Approved
Voriconazole	The metabolism of Meprobamate can be decreased when combined with Voriconazole.	Approved, Investigational
Vortioxetine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Vortioxetine.	Approved
Yohimbine	The therapeutic efficacy of Meprobamate can be decreased when used in combination with Yohimbine.	Approved, Vet Approved
Zaleplon	The risk or severity of adverse effects can be increased when Meprobamate is combined with Zaleplon.	Approved, Illicit, Investigational
Ziconotide	The risk or severity of adverse effects can be increased when Meprobamate is combined with Ziconotide.	Approved
Zidovudine	The serum concentration of Zidovudine can be increased when it is combined with Meprobamate.	Approved
Zimelidine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Zimelidine.	Withdrawn
Ziprasidone	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Meprobamate.	Approved
Zolpidem	Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.	Approved
Zonisamide	The risk or severity of adverse effects can be increased when Meprobamate is combined with Zonisamide.	Approved, Investigational
Zopiclone	The risk or severity of adverse effects can be increased when Meprobamate is combined with Zopiclone.	Approved
Zotepine	The risk or severity of adverse effects can be increased when Meprobamate is combined with Zotepine.	Approved
Zuclopenthixol	The risk or severity of adverse effects can be increased when Meprobamate is combined with Zuclopenthixol.	Approved, Investigational

Food Interactions

Take without regard to meals. Avoid alcohol.

References

Synthesis Reference

Not Available

General References

Not Available

External Links

Resource	Link
Human Metabolome Database (HMDB)	HMDB14515
KEGG Drug	D00376
PubChem Compound	4064
PubChem Substance	46508142
ChemSpider	3924
ChEBI	6761
ChEMBL	CHEMBL979
Therapeutic Targets Database	DAP001507
PharmGKB	PA450377
Drug Product Database	10233
RxList	http://www.rxlist.com/cgi/generic2/meprobamate.htm
Drugs.com	http://www.drugs.com/cdi/meprobamate.html
PDRhealth	http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/mil1268.shtml
Wikipedia	Meprobamate

ATC Codes

N05BC51 — Meprobamate, combinations

N05CX01 — Meprobamate, combinations

N05BC01 — Meprobamate

AHFS Codes

Not Available

PDB Entries

Not Available

FDA label

Not Available

MSDS

Download (52.6 KB)

Clinical Trials

Not Available

Pharmacoeconomics

Manufacturers

Glaxosmithkline llc
Medpointe pharmaceuticals medpointe healthcare inc
Wyeth ayerst laboratories
Ferndale laboratories inc
Alra laboratories inc
Teva pharmaceuticals usa inc
Alembic ltd
Barr laboratories inc
Elkins sinn div ah robins co inc
Heather drug co inc
Impax laboratories inc
Invagen pharmaceuticals inc
Ivax pharmaceuticals inc sub teva pharmaceuticals usa
Ivc industries inc dba inverness medical nutritionals group
Lannett co inc
Lederle laboratories div american cyanamid co
Km lee laboratories inc
Mallard inc
Mk laboratories inc
Mutual pharmaceutical co inc
Mylan pharmaceuticals inc
Nexgen pharma inc
Parke davis div warner lambert co
L perrigo co
Pharmavite pharmaceuticals
Purepac pharmaceutical co
Private formulations inc
Roxane laboratories inc
Sandoz inc
Scherer laboratories inc
Solvay pharmaceuticals
Stanlabs pharmaceutical co sub simpak corp
Tablicaps inc
Usl pharma inc
Valeant pharmaceuticals international
Vangard laboratories inc div midway medical co
Watson laboratories inc
West ward pharmaceutical corp
Whiteworth towne paulsen inc
Halsey drug co inc

Packagers

Dosage forms

Form	Route	Strength
Tablet	Oral
Tablet	Oral	400 mg
Tablet	Oral	200 mg/1
Tablet	Oral	400 mg/1
Tablet	Oral	200 mg

Prices

Unit description	Cost	Unit
Mepron 750 mg/5ml Suspension	5.41USD	ml
Mepron 750 mg/5 ml suspension	4.95USD	ml
Meprobamate 200 mg tablet	1.42USD	tablet
Meprobamate 400 mg tablet	0.84USD	tablet
Meprozine 50-25 mg capsule	0.78USD	capsule

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
CA1336266	No	1995-07-11	2012-07-11	Canada
CA2152615	No	2001-10-16	2013-12-23	Canada
US4981874	No	1992-08-15	2009-08-15	US
US6649659	No	1997-01-10	2017-01-10	US

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	105 °C	PhysProp
water solubility	4700 mg/L (at 25 °C)	YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP	0.70	HANSCH,C ET AL. (1995)
logS	-1.67	ADME Research, USCD

Predicted Properties

Property	Value	Source
Water Solubility	2.47 mg/mL	ALOGPS
logP	1.06	ALOGPS
logP	0.93	ChemAxon
logS	-1.9	ALOGPS
pKa (Strongest Acidic)	15.17	ChemAxon
Physiological Charge	0	ChemAxon
Hydrogen Acceptor Count	2	ChemAxon
Hydrogen Donor Count	2	ChemAxon
Polar Surface Area	104.64 Å²	ChemAxon
Rotatable Bond Count	8	ChemAxon
Refractivity	53.04 m³·mol^-1	ChemAxon
Polarizability	22.65 Å³	ChemAxon
Number of Rings	0	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.9534
Blood Brain Barrier	+	0.9864
Caco-2 permeable	-	0.5731
P-glycoprotein substrate	Non-substrate	0.5282
P-glycoprotein inhibitor I	Non-inhibitor	0.8781
P-glycoprotein inhibitor II	Non-inhibitor	0.9033
Renal organic cation transporter	Non-inhibitor	0.945
CYP450 2C9 substrate	Non-substrate	0.9108
CYP450 2D6 substrate	Non-substrate	0.8961
CYP450 3A4 substrate	Non-substrate	0.7032
CYP450 1A2 substrate	Non-inhibitor	0.8381
CYP450 2C9 inhibitor	Non-inhibitor	0.8799
CYP450 2D6 inhibitor	Non-inhibitor	0.8764
CYP450 2C19 inhibitor	Non-inhibitor	0.8754
CYP450 3A4 inhibitor	Non-inhibitor	0.8735
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.8914
Ames test	Non AMES toxic	0.8706
Carcinogenicity	Non-carcinogens	0.7304
Biodegradation	Not ready biodegradable	0.965
Rat acute toxicity	2.4075 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9943
hERG inhibition (predictor II)	Non-inhibitor	0.9322

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)

Download (10.1 KB)

Spectra

Spectrum Type	Description	Splash Key
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , positive	splash10-0a4i-1900000000-8dd8e00d9af9bce5cd26	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , positive	splash10-052b-9100000000-c21398e92cac7b48f567	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , positive	splash10-0a4i-9000000000-dd49a24a00b896129dbb	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , positive	splash10-0a4i-9000000000-c537c5c82280244f0974	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , positive	splash10-0a4i-9000000000-f351c8e0d2b10b45fdc9	View in MoNA
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Negative	Not Available

Taxonomy

Description

This compound belongs to the class of organic compounds known as carbamate esters. These are compounds containing an ester of carbamic acid with the general structure R2NC(=O)OR' (R' not H). They are esters of carbamic acids.

Kingdom

Organic compounds

Super Class

Organic acids and derivatives

Class

Carboxylic acids and derivatives

Sub Class

Amino acids, peptides, and analogues

Direct Parent

Carbamate esters

Alternative Parents

Organic carbonic acids and derivatives / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds

Substituents

Carbamic acid ester / Carbonic acid derivative / Organic nitrogen compound / Organic oxygen compound / Organopnictogen compound / Organic oxide / Hydrocarbon derivative / Organooxygen compound / Organonitrogen compound / Carbonyl group

Molecular Framework

Aliphatic acyclic compounds

External Descriptors

Not Available

Targets

Details

1. Gamma-aminobutyric acid receptor subunit alpha-1

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: agonist

General Function:: Inhibitory extracellular ligand-gated ion channel activity
Specific Function:: Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:: GABRA1
Uniprot ID:: P14867
Uniprot Name:: Gamma-aminobutyric acid receptor subunit alpha-1
Molecular Weight:: 51801.395 Da

References

Details

2. Gamma-aminobutyric acid receptor subunit alpha-2

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: agonist

General Function:: Inhibitory extracellular ligand-gated ion channel activity
Specific Function:: GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:: GABRA2
Uniprot ID:: P47869
Uniprot Name:: Gamma-aminobutyric acid receptor subunit alpha-2
Molecular Weight:: 51325.85 Da

References

Details

3. Gamma-aminobutyric acid receptor subunit alpha-3

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: agonist

General Function:: Inhibitory extracellular ligand-gated ion channel activity
Specific Function:: GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:: GABRA3
Uniprot ID:: P34903
Uniprot Name:: Gamma-aminobutyric acid receptor subunit alpha-3
Molecular Weight:: 55164.055 Da

References

Details

4. Gamma-aminobutyric acid receptor subunit alpha-4

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: agonist

General Function:: Inhibitory extracellular ligand-gated ion channel activity
Specific Function:: GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:: GABRA4
Uniprot ID:: P48169
Uniprot Name:: Gamma-aminobutyric acid receptor subunit alpha-4
Molecular Weight:: 61622.645 Da

References

Details

5. Gamma-aminobutyric acid receptor subunit alpha-5

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: agonist

General Function:: Transporter activity
Specific Function:: GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:: GABRA5
Uniprot ID:: P31644
Uniprot Name:: Gamma-aminobutyric acid receptor subunit alpha-5
Molecular Weight:: 52145.645 Da

References

Details

6. Gamma-aminobutyric acid receptor subunit alpha-6

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: agonist

General Function:: Inhibitory extracellular ligand-gated ion channel activity
Specific Function:: GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:: GABRA6
Uniprot ID:: Q16445
Uniprot Name:: Gamma-aminobutyric acid receptor subunit alpha-6
Molecular Weight:: 51023.69 Da

References

Details

7. GABA-A receptor (anion channel) (Protein Group)

Kind: Protein group
Organism: Human
Pharmacological action: yes
Actions: positive allosteric modulator

General Function:: Inhibitory extracellular ligand-gated ion channel activity
Specific Function:: Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).

Components:

Name	UniProt ID	Details
Gamma-aminobutyric acid receptor subunit alpha-1	P14867	Details
Gamma-aminobutyric acid receptor subunit alpha-2	P47869	Details
Gamma-aminobutyric acid receptor subunit alpha-3	P34903	Details
Gamma-aminobutyric acid receptor subunit alpha-4	P48169	Details
Gamma-aminobutyric acid receptor subunit alpha-5	P31644	Details
Gamma-aminobutyric acid receptor subunit alpha-6	Q16445	Details
Gamma-aminobutyric acid receptor subunit beta-1	P18505	Details
Gamma-aminobutyric acid receptor subunit beta-2	P47870	Details
Gamma-aminobutyric acid receptor subunit beta-3	P28472	Details
Gamma-aminobutyric acid receptor subunit delta	O14764	Details
Gamma-aminobutyric acid receptor subunit epsilon	P78334	Details
Gamma-aminobutyric acid receptor subunit gamma-1	Q8N1C3	Details
Gamma-aminobutyric acid receptor subunit gamma-2	P18507	Details
Gamma-aminobutyric acid receptor subunit gamma-3	Q99928	Details
Gamma-aminobutyric acid receptor subunit pi	O00591	Details
Gamma-aminobutyric acid receptor subunit theta	Q9UN88	Details

References

Enzymes

Details

1. Cytochrome P450 2C19

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Steroid hydroxylase activity
Specific Function:: Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:: CYP2C19
Uniprot ID:: P33261
Uniprot Name:: Cytochrome P450 2C19
Molecular Weight:: 55930.545 Da

References

Details

2. Cytochrome P450 2E1

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Steroid hydroxylase activity
Specific Function:: Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:: CYP2E1
Uniprot ID:: P05181
Uniprot Name:: Cytochrome P450 2E1
Molecular Weight:: 56848.42 Da

References

Transporters

Details

1. Multidrug resistance protein 1

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitor

General Function:: Xenobiotic-transporting atpase activity
Specific Function:: Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:: ABCB1
Uniprot ID:: P08183
Uniprot Name:: Multidrug resistance protein 1
Molecular Weight:: 141477.255 Da

References

Drug created on June 13, 2005 07:24 / Updated on July 18, 2017 16:48

Get DrugBank to go!

Structure for DB00371 (Meprobamate)

Targets

References

References

References

References

References

References

Components:

References

Enzymes

References

References

Transporters

References